


HM03

Cat. No.:	HY-125974		
CAS No.:	500565-15-1		
Molecular Formula:	C ₂₆ H ₂₇ ClN ₄ O ₂		
Molecular Weight:	462.97		
Target:	HSP		
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (270.00 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1600 mL	10.7998 mL	21.5997 mL
		5 mM	0.4320 mL	2.1600 mL	4.3199 mL
10 mM		0.2160 mL	1.0800 mL	2.1600 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (13.50 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	HM03 is a potent and selective HSPA5 (Heat shock 70kDa protein 5, also known as Bip, Grp78) inhibitor. HM03 has anticancer activity ^[1] .
IC₅₀ & Target	HSPA5
In Vitro	HM03 (0.1-50 μM; 72 hours) exhibits over 50% inhibition at 25 μM concentration in HCT116 cells ^[1] . HM03 forms more binding interactions with HSPA5 and HSPA9 than with the other HSP70 proteins ^[1] . HM03 exhibits promising inhibition activities from cancer cell viability and tumor inhibition assays ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]

Cell Line:	HCT116 cells
Concentration:	0.1, 1, 10, 25, 50 μ M
Incubation Time:	72 hours
Result:	Exhibited prominent inhibition effect (18% survival at 25 μ M).

REFERENCES

[1]. Huang M, et al. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors. *Bioorg Med Chem Lett*. 2013;23(10):3044-3050.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA